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Sporadic inclusion body myositis (s-IBM) is the most
frequently acquired myopathy above the age of 50 years.
Although the pathogenesis of s-IBM is largely unknown,
an underlying myodegenerative process involving amyloid
b protein (Ab) accumulation has been proposed as a
pathophysiological mechanism [1]. Here, we examined
whether there are changes in the plasma levels of Ab42 and
Ab40 in patients with s-IBM, patients with other inﬂam-
matory myopathies, and age-matched controls.
All patients diagnosed with an inﬂammatory myopathy
before January 2006 were retrieved from the Dutch neu-
romuscular database (CRAMP = Computer Registry of
All Myopathies and Polyneuropathies) [4]. Of the 152
registered patients, 49 patients were excluded because they
could not be traced (n = 11), were deceased (n = 26) or
declined to participate (n = 12). We included 31 patients
with s-IBM, 49 with polymyositis (PM) and 23 with
dermatomyositis (DM). Thirty-four neurologically healthy
spouses were selected as age-matched controls. Diagnosis
of s-IBM, DM and PM was made according to established
international criteria [3, 5]. Patients were visited at home.
Functional status was scored using the modiﬁed Rankin-
scores, and the Barthel index. Furthermore, total body
weight, use of steroids or other immunosuppressive medi-
cation and statins (HMG-CoA reductase inhibitors) were
noted. Local ethical committee approval, and written
informed consent from all participants, was obtained.
Plasmasampleswerealiquotedandfrozenat-80Cuntil
the time of analysis. Plasma concentrations of Ab42 were
measured by a commercial ELISA (Innotest b-amyloid(1–42)
High Sensitivity Test; Innogenetics, Gent, Belgium). Ab40
concentrations were measured by a commercially available
assaybasedonthexMAPtechnology(Biosource,Camarillo,
CA, USA) on a LiquiChip 100S analyzer (Qiagen, Venlo,
The Netherlands).
Comparisons of the plasma values between the groups
were made using one-way ANOVA with Tukey post hoc
test on logarithmically transformed data with covariate
analysis of the baseline characteristics. Correlations
between variables were calculated using Pearson’s corre-
lation coefﬁcient. SPSS version 14.0 was used to analyze
the data.
Baseline characteristics and plasma Ab are shown in
Tables 1 and 2. The median plasma Ab42 levels were
signiﬁcantly increased in the s-IBM group versus controls
and PM group. When we divided the s-IBM patients into
two groups, with concentrations either above or below the
median levels of Ab42, we neither found any differences in
demographic data nor in disease severity. Also, age or
Rankin-scores or Barthel index, medication use, time
interval from blood draw to spinning and freezing or other
baseline characteristics did not correlate with Ab42 or Ab40
levels in the individual groups.
This is the ﬁrst study examining plasma levels of Ab42
in patients with s-IBM compared to patients with other
inﬂammatory myopathies and age-matched controls. Data
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DOI 10.1007/s00401-009-0554-8of other studies hint to a degenerative contribution to the
cause of s-IBM, where it was shown that intracellular
amyloid deposits and Ab immunoreactivity were found in
affected muscle ﬁbers of patients with s-IBM [1]. In
addition, recent transgenic mice studies have shown that
the deposition of Ab may be a primary pathogenic mech-
anism in s-IBM [2].
This cross-sectional cohort study was designed for the
sole purpose to test the hypothesis that the underlying
neurodegenerative process in s-IBM could be reﬂected in
altered Ab plasma levels. Because of this design, plasma
Ab levels could not be correlated to the results of the
muscle biopsies, because in many patients the diagnosis
was made several years before we collected the plasma.
Lack of matching in baseline characteristics (due to the
intrinsic clinical characteristics of the included disorders)
did not explain the differences in Ab levels. Surprisingly,
plasma Ab levels were also increased in DM. A possible
confounding factor could be that some of the DM
patients could have developed IBM at time of this study,
since there were older patients included in this group and
the diagnosis was made previously, i.e., we did not
perform new biopsies in patients that were diagnosed
previously. Furthermore, kidney function can inﬂuence
amyloid levels. Only one DM patient had a previous
kidney problem in his medical history. The Ab plasma
concentrations of this patient were within the range of his
group. However, speciﬁc laboratory data of kidney
functions at time of the study were not available. The
potential diagnostic value of plasma Ab testing seems
limited in our cross-sectional cohort because of the
considerable overlap in concentrations. Further prospec-
tive investigations are required, to fully elucidate this
and, in addition, to evaluate if plasma Ab concentrations
could be correlated to the severity or long-term outcome
of this enigmatic disease.
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